20B Stock Chart & Stats
€0.28
>-€0.01(-0.64%)
At close: 4:00 PM EDT
€0.28
>-€0.01(-0.64%)
Day’s Range― - ―
52-Week Range€0.15 - €0.42
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€32.47M
Enterprise Value€58.98
Total Cash (Recent Filing)€788.32K
Total Debt (Recent Filing)€1.27M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding106,483,440
10 Day Avg. Volume150
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)180.94
Price to Sales (P/S)1001.91
P/FCF Ratio-54.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Diagnostic FocusA focused blood-based diagnostics model gives BioMark a clear strategic identity within medical research. Concentrating on metabolic biomarkers and early detection may help align development resources around clinically important applications and build expertise across related diagnostic programs.
Clinical Development PlatformThe company is pursuing assay development and clinical validation rather than only basic research, creating a pathway toward usable diagnostic applications. Progress across screening and monitoring indications could broaden the platform’s long-term commercial relevance if validation succeeds.
Equity Has Returned PositivePositive equity in the latest FY2025 and TTM periods is an improvement from the negative-equity years previously reported. Although the balance sheet remains strained, this change provides a stronger capital base than the company had during its earlier periods of pronounced financial stress.
Bears Say
Sharp Revenue ContractionThe steep recent revenue contraction indicates that the company has not yet established a stable growth engine for its diagnostic programs. Smaller revenue reduces operating leverage and makes it harder to fund research, validation, and commercialization without additional financing.
Persistent Unprofitable OperationsNegative gross profit and substantial operating losses show that current activities are not covering the cost of generating revenue. Persistent losses weaken internal funding capacity and suggest that margin improvement or materially greater scale is needed before earnings can become sustainable.
Cash Burn And Elevated LeverageOngoing operating and free-cash-flow deficits mean the business is not self-funding and remains dependent on external capital. At the same time, debt exceeding twice equity increases financing pressure, potentially limiting flexibility to sustain development and absorb further losses.
BioMark Diagnostics News
20B FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was €0.15 and its highest was €0.42 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is €32.47M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Nov 27, 2026 which is in 78 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Jul 29, 2026. The company reported -€0.002 earnings per share for the quarter.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 106,483,440 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in DE:20B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―